Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of HL231 inhalation solution in chronic obstructive pulmonary disease
CTR20233812Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HL231 Solution for Inhalation, indacaterol, glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Nov 2023; status: completed.
02
Drugs
HL231 Solution for Inhalationindacaterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20233812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233812.